Hims vs REMEVi
Hims and REMEVi both sell semaglutide and tirzepatide; this is how their prices, coverage and records differ.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Hims
Best for: knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC
Visit Hims →
REMEVi
Best for: coverage in all 50 states, which most sellers will not confirm
Visit REMEVi →If you are choosing between Hims and REMEVi, price alone will not settle it. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. REMEVi leads our six-part score, 7.8 to 6.8. One of the two has an FDA warning letter on record, covered below.
Hims vs REMEVi price
Hims and REMEVi start at the same figure, $199 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.
Drug by drug: Semaglutide costs the same at both, $199 a month; tirzepatide is cheaper at REMEVi ($269 a month vs $299 a month).
Medications and formats
Both sell semaglutide and tirzepatide.
On format, Hims prices compounded injections and brand-name pens, while REMEVi prices compounded injections.
If you want the FDA-approved brand rather than a compounded version, Hims is the only one of the two with a brand-name price.
Where each one treats patients
Hims lists 50 states, and REMEVi lists 51 states.
They overlap in 50 states. REMEVi alone covers District of Columbia.
Pricing
Hims
Brand Zepbound from $299/mo medication-only; requires Hims Weight Loss Membership ($149/mo)
REMEVi
52-week plan; month-to-month $279/mo. Same price every month (no titration hikes)
52-week plan; month-to-month $339/mo
What each price covers
Both prices cover the medication itself.
REMEVi's price also covers the clinician visit and shipping, which Hims does not claim.
Hims is silent on shipping and lab work.
REMEVi is silent on lab work and coaching.
Hims
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
REMEVi
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Where each one scores higher
Overall, REMEVi scores 7.8 and Hims 6.8 out of 10.
REMEVi is stronger on value (4.5 vs 3.0), trust & safety (8.5 vs 7.0) and support (7.0 vs 3.0).
Effectiveness, user experience and accessibility are within half a point.
Hims
6.8/10
REMEVi
7.8/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent Hims a warning letter dated September 9, 2025 (letter 716567), and it is still open.
REMEVi has no FDA warning letter on record with us.
Features & Coverage
| Feature | Hims | REMEVi |
|---|---|---|
| Starting Price | $199/mo | $199/mo |
| Features | 2 features | ✓8 features |
| States Available | 50 | ✓51 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | 1 letter | ✓None |
About Hims
Hims is a major men's telehealth brand. Its weight loss offering is compounded semaglutide on a 6-month plan.
Read our full Hims review →About REMEVi
On the 52-week plan compounded semaglutide starts at $199/mo and tirzepatide at $269/mo, the same figure every month, nothing hidden, cancellable at will. REMEVi claims to be the first GLP-1 telehealth clinic working bilingually in English and Spanish, with clinicians trained in both rather than anything auto-translated. Providers manage titration weekly and an NPI-verified pharmacy ships overnight. Certification is LegitScript and licensure covers all 50 states plus DC. It discloses that compounded drugs are not FDA-approved. That pharmacy is verified by NPI but never named.
Read our full REMEVi review →Pros & Cons
Hims
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
- Names 4 pharmacies that fill its prescriptions, which most sellers do not
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- The FDA has issued Hims a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
REMEVi
What we like
- Semaglutide costs $199 a month, close to the $185 median for compounded semaglutide across the sellers we compare
- Tirzepatide costs $269 a month, close to the $250 median for compounded tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
- Serves all 50 states
- We found no FDA warning letters issued to REMEVi
Watch-outs
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
REMEVi wins this one, 7.8 to 6.8, above all for coverage in all 50 states, which most sellers will not confirm. Hims fits better if knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC is your priority.
Choose Hims if…
You want knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC and an opening price near $199 a month.
Choose REMEVi if…
You want coverage in all 50 states, which most sellers will not confirm and an opening price near $199 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Trimi Health
Knowing which pharmacy fills the vial: it names VialsRx
From $99/mo
Get started →ShedRx
Oral orforglipron alongside the injectables
From $149/mo
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →Hims vs REMEVi: FAQ
Close alternatives to Hims and REMEVi
- Hims vs Hers
- Hims vs Care Bare Rx
- Hims vs Concierge MD LA
- Hims vs Corsica Health
- REMEVi vs Hers
- REMEVi vs Curex
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.